Canada’s National Advisory Committee on Immunization (NACI) now recommends expanding the use of the AstraZeneca-Oxford vaccine to all Canadians over the age of 30, but only when the benefits outweigh the risks of rare, serious post-vaccine blood clots.
The advisory body issued its latest guidance on Friday after reviewing new provincial data on the high level of risk currently posed in Canada by COVID-19.
